As reported earlier, RBC Capital analyst Brian Abrahams downgraded Intercept Pharmaceutical to Sector Perform from Outperform and kept his $115 price target on valuation, saying that the stock has appreciated 90% year-to-date after what he had called an "inappropriately sharp selloff" on OCA concerns. The analyst says the current price is now more reflective of the risk-reward heading into the release of phase 3 REGENERATE NASH data in the first half of next year, adding that the program is "more likely than not" to be successful. Abrahams adds that investors should use any weakness to add to positions.